bioMérieux
€76.10Change from previous close: −1.42%Absolute change: −€1.10
Valuation
Data as of October 2, 2026
Valuation multiples
- Market cap
- €8.98B
- Enterprise value
- €8.85B
- P/E (trailing 12 months)
- 19.5
- Forward P/E
- 16.3
- PEG
- 1.80
- Price/book
- 2.08
- Price/sales
- 2.25
- EV/EBITDA
- 8.43
- EV/revenue
- 2.22
Profitability and growth
- Gross margin
- 56.1%
- Operating margin
- 15.2%
- Net margin
- 11.6%
- ROE
- 11.2%
- ROA
- 7.2%
- Revenue growth (year over year)
- -3.9%
- Earnings growth (year over year)
- 41.9%
Financial health
- Total cash
- €657.7M
- Total debt
- €421.8M
- Debt/equity
- 0.10
- Current ratio
- 2.30
- Quick ratio
- 1.44
Dividends
- Annual dividend per share
- €0.98
- Dividend yield
- 1.3%
- Payout ratio
- 25.1%
- Ex-dividend date
- June 9, 2026
Analysts and estimates
- Average price target
- €79.54
- Median price target
- €80.00
- High price target
- €100.00
- Low price target
- €66.00
- Analysts with a price target
- 14
- Consensus
- Hold
- Forward EPS
- €4.66
- EPS estimate, current year
- €4.34
Shares and trading
- Beta
- 0.58
- Average volume
- 162.48K
- Shares outstanding
- 117.95M
- Float
- 40.02M
- Institutional ownership
- 16.3%
- Insider ownership
- 66.5%